In a 68- and 72-week clinical trial studying Wegovy (2.4 mg), brand-name Semaglutide, and Zepbound (15 mg), brand-name Tirzepatide, in patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15% and 20% respectively, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone)
How to Manage The Blahs Adjust the dose
For individuals with obesity, the weight loss facilitated by semaglutide can improve the efficacy of TRT by reducing the conversion of testosterone to estrogen in adipose tissue and enhancing the overall hormonal profile
MeAgain is the better fit for a trusted daily GLP-1 tracker and companion
Eligibility will be determined through an intake questionnaire followed by a comprehensive telehealth consultation, considering factors like medical history, current health status, and weight loss goals
This personalized approach helps maximize the benefits of skinny shots while supporting your long-term weight management success
